FDA Selects Seven Pharmaceutical Companies for PreCheck Supply Chain Pilot Program

The U.S. Food and Drug Administration (FDA) has selected seven pharmaceutical companies, including Eli Lilly and Regeneron, to participate in the inaugural PreCheck pilot program. This initiative establishes a new regulatory framework designed to strengthen the security and efficiency of the national drug supply chain.

The pilot program evaluates participating companies under a streamlined oversight process intended to expedite the movement of pharmaceutical products. By integrating these seven firms into the PreCheck scheme, the FDA aims to test new methods for monitoring manufacturing and distribution standards. The agency launched this framework to address vulnerabilities within the supply chain and to ensure that high-priority medications reach patients more reliably. The participating companies will now operate under these updated protocols as the FDA assesses the long-term viability of the program for the broader industry.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 30, 2026

Author

GOAI